Form 4: Xeris Biopharma CLO Beth Hecht Sells Shares

Chief Legal Officer Beth Hecht sold 16,667 shares of Xeris Biopharma Holdings, Inc. via a pre-arranged 10b5-1 trading plan.

Summary

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., sold 16,667 shares of common stock.
• The transaction occurred on May 1, 2026, at a weighted average price of $6.2282 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan.
• Following the transaction, the reporting person retains beneficial ownership of 1,193,173 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 arrangement, which is standard practice for corporate officers.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in the short-term stock price performance.

Risks

• Market volatility affecting the share price of XERS.
• Reliance on Rule 10b5-1 plans does not eliminate the inherent risk of market perception regarding insider divestment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the biotechnology sector, often used by executives for liquidity and diversification purposes rather than signaling fundamental changes in company outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executive stock sales to ensure compliance with SEC regulations.
• The volume of shares sold represents a small fraction of the total holdings, which is consistent with typical executive portfolio management.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the officer's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Xeris Biopharma, XERS, Insider Trading, Form 4, Beth Hecht, Biotech